The Market At Work: EpiPen Parent Company’s Stock Plummets
By Micah J. Fleck In response to the outrageous rise in price for EpiPen, the star product of parent company Mylan, consumers are not happy. They are leaving the company’s patronage in droves and instead turning to alternatives such as Adrenaclick. The main reason why these alternatives are not big sellers is because they are…